Changhua site meets international regulatory standards for global medical applications
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Subscribe To Our Newsletter & Stay Updated